CC motif chemokine ligand 19 suppressed colorectal cancer in vivo accompanied by an increase in IL-12 and IFN-γ

Biomed Pharmacother. 2015 Feb:69:374-9. doi: 10.1016/j.biopha.2014.12.032. Epub 2014 Dec 24.

Abstract

In this study we investigate the role of CC motif chemokine ligand 19 (CCL19) to colorectal cancer (CRC) in vivo. We injected different dose of recombinant mouse CCL19 (rmCCL19) in the tumor site of the model of transplanted tumor. Result shows that rmCCL19 can suppress CRC tumorigenesis and growth in vivo, and it can also prolong overall survival of mice. Quantitative reverse transcription-polymerase chain reaction and enzyme linked immunosorbent assay results showed that the interferon-γ (IFN-γ) and interleukin-12 (IL-12) levels in the tumors and plasma were significantly enhanced after processing with rmCCL19.

Keywords: Chemokine CCL19; Colorectal cancer; Immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinogenesis / drug effects
  • Carcinogenesis / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Chemokine CCL19 / pharmacology*
  • Colorectal Neoplasms / metabolism*
  • Colorectal Neoplasms / pathology*
  • Dose-Response Relationship, Drug
  • Interferon-gamma / genetics
  • Interferon-gamma / metabolism*
  • Interleukin-12 / genetics
  • Interleukin-12 / metabolism*
  • Male
  • Mice, Inbred BALB C
  • Mice, Nude
  • Recombinant Proteins / pharmacology
  • Tumor Burden / drug effects

Substances

  • Ccl19 protein, mouse
  • Chemokine CCL19
  • Recombinant Proteins
  • Interleukin-12
  • Interferon-gamma